河北省晚期食管鳞癌免疫治疗现状及进展  

Research Status and Progress on Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma in Hebei Province

作　　者：段晓阳[1] 史健[1] DUAN Xiaoyang;SHI Jian(Department of Medical Oncology,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China)

机构地区：[1]河北医科大学第四医院肿瘤内科,石家庄050011

出　　处：《肿瘤防治研究》2025年第2期103-109,共7页Cancer Research on Prevention and Treatment

摘　　要：食管鳞状细胞癌是河北省最常见的消化道恶性肿瘤之一,因早期症状不典型,多数患者确诊时已为晚期,不适合手术治疗,多采用内科综合治疗,但治疗效果欠佳,预后差。近年来,免疫治疗的出现给晚期食管鳞癌患者带来了希望,较大程度地改善了患者预后,但仍存在免疫耐药、疗效预测指标选择、优势人群筛选、联合治疗策略的选择等困惑。因此,基于河北省食管鳞癌的高发病率及预后差情况,本文将对晚期食管鳞癌治疗的研究进展进行简要综述,希望为晚期食管癌的治疗策略提供参考。Esophageal squamous cell carcinoma(ESCC)is one of the most prevalent gastrointestinal cancers in Hebei province.Most patients are diagnosed at an advanced stage due to untypical early symptoms,making surgical treatment often unfeasible.As a result,most of them are treated with comprehensive medical treatment,which tends to have limited effectiveness and poor prognosis.However,the recent introduction of immunotherapy has considerably advanced treatment options for patients with advanced ESCC,notably improving their prognosis.Uncertainties regarding immune resistance,the selection of predictive indicators of efficacy,the identification of dominant population,and the choice of combined treatment strategies are still evident.Therefore,based on the high incidence and poor prognosis of ESCC in Hebei Province,this article will briefly review the research progress in the treatment of advanced ESCC,aiming to provide guidance for treatment strategies for advanced esophageal cancer.

关 键 词：食管鳞状细胞癌 免疫治疗 研究进展 

分 类 号：R735.1[医药卫生—肿瘤]